HHS Seeks Partners for Novel Cancer Immunotherapy Research and Licensing

What this means for your practice

This notice primarily targets pharmaceutical companies, biotechnology firms, and academic research institutions with capabilities in drug development and commercialization. For telehealth brands, medspas, dental practices, or chiropractic offices, this specific regulatory notice does not directly impact current operational compliance or service delivery models. However, it represents a long-term development in medical science that could eventually lead to new therapeutic options, which may, years down the line, influence patient care pathways. Operators should be aware of such advancements as part of a general understanding of the evolving healthcare landscape, but no immediate compliance actions are required based on this technology licensing opportunity.

Washington D.C. – The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), has issued a notice announcing the availability of a government-owned invention for licensing. The NCI is actively seeking research co-development partners and/or licensees for a promising viral peptide (CE1)-based therapeutic intended for the prevention and treatment of hepatocellular carcinoma (HCC).

The Challenge of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) stands as a highly aggressive and common primary liver cancer, disproportionately affecting individuals with underlying chronic liver diseases like hepatitis and cirrhosis. Globally, HCC continues to contribute significantly to cancer-related mortality, with both its incidence and death rates on the rise. Current methods for early detection, surveillance, and treatment are often suboptimal due to the intricate biology of the tumor and its complex etiologies.

A Novel Immunotherapeutic Approach

NCI researchers have made a significant discovery through extensive serological profiling across three independent cohorts. They identified a common epitope, designated CE1, which is shared among protective viral antigens. This CE1 epitope was found to be notably enriched in healthy individuals when compared to patients diagnosed with HCC.

Further investigation demonstrated that a synthetic CE1 peptide possesses the capability to elicit a T cell response specifically targeting HCC cells. This critical finding indicates that CE1 can be developed into an immunotherapy for HCC, with a CE1-based HCC vaccine identified as a potential application. Given the scarcity of effective therapeutic options currently available for HCC patients, the development of novel treatments, such as this, promises substantial commercial and public health benefits.

Technology Details and Advantages

The technology described in the notice is classified as a Therapeutic, with Oncology as its primary therapeutic area. It is currently in the Discovery stage of development. The NCI has identified several competitive advantages for this CE1 peptide:

• Correlation with Improved Outcomes: VirScan data provides evidence that this peptide correlates with better outcomes not only in HCC but also in breast cancer.
• Immunomodulatory Effect: The CE1 peptide exhibits an immunomodulatory effect, positioning immunomodulators as a promising avenue in cancer treatment.
• Biological Activity: It is biologically active in inducing T cell cytolytic activity.
• Specificity: The peptide demonstrates HCC cell killing in an HLA-specific manner.

Potential commercial applications for this invention extend beyond just prevention and treatment, encompassing its use as a predictive biomarker for HCC risk, a component in serological response tests, a tool for patient stratification for CE1-based therapy, and for monitoring the efficacy of a CE1-based vaccine.

Collaboration and Licensing Opportunity

This notice, issued in accordance with 37 CFR 404.4, which grants authority to license government-owned inventions, serves as an open invitation for collaboration. The NCI is actively seeking partnerships for licensing and/or co-development research collaborations to advance CE1-based therapeutics for HCC prevention and treatment.

Interested parties are encouraged to direct inquiries related to this licensing opportunity to Kevin Chang, Ph.D., Technology Transfer Manager at the NCI Technology Transfer Center.

Key Facts

| Detail | Value | |---|---| | Agency | National Institutes of Health, HHS | | Action | Notice seeking research co-development partners/licensees | | Technology Focus | Viral peptide (CE1)-based therapeutics for Hepatocellular Carcinoma (HCC) | | Development Stage | Discovery | | Potential Applications | HCC prevention, treatment, predictive biomarker, patient stratification, monitoring vaccine efficacy | | Contact for Inquiries | Kevin Chang, Ph.D., NCI, [email protected] |

Frequently Asked Questions

What is the main purpose of this HHS notice?

The main purpose is for the National Cancer Institute (NCI) to seek research co-development partners and/or licensees for a government-owned invention related to viral peptide (CE1)-based therapeutics for hepatocellular carcinoma (HCC) prevention and treatment.

What type of cancer does this technology address?

This technology specifically addresses Hepatocellular Carcinoma (HCC), which is an aggressive primary liver cancer. The source also mentions VirScan data correlating with better outcomes in breast cancer.

What is 'CE1' and how does it work?

CE1 is a common epitope (viral peptide) identified by NCI researchers that is enriched in healthy individuals compared to HCC patients. A synthetic CE1 peptide has been shown to elicit a T cell response to HCC cells, suggesting its utility as an immunotherapy, such as a CE1-based HCC vaccine.

Is this technology ready for patient use?

No, the development stage is currently classified as 'Discovery.' The NCI is seeking partners for co-development and licensing, indicating it is in early research phases and not yet available for clinical application.

Who should contact NCI regarding this opportunity?

Inquiries related to this license opportunity should be directed to Kevin Chang, Ph.D., Technology Transfer Manager, NCI, Technology Transfer Center. This opportunity is primarily for entities interested in research collaboration, licensing, and commercial development of therapeutics.

Source: HHS — Notice: Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy · 2026-07-02